Opinion|Videos|January 5, 2026
Use of Xanomeline/Trospium in Clinical Practice
Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.
Advertisement
Episodes in this series
Panelists discuss how clinicians are beginning to integrate xanomeline/trospium into practice for patients who have struggled with traditional therapies. They share early observations of improved engagement and cognitive clarity.
Panelists discuss how appropriate patient selection, titration, and adverse effect monitoring are key to maximizing outcomes.
Panelists discuss how broad adoption depends on payer coverage and growing real-world data validating long-term safety and effectiveness.
Advertisement
Related to this article
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5